Epigenomics Competitors

Olink Holding AB (publ) (NASDAQ:OLK) and Epigenomics (OTCMKTS:EPGNY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Olink Holding AB (publ) and Epigenomics, as provided by MarketBeat.com.

Earnings & Valuation

This table compares Olink Holding AB (publ) and Epigenomics' top-line revenue, earnings per share and valuation.

Profitability

This table compares Olink Holding AB (publ) and Epigenomics' net margins, return on equity and return on assets.

Epigenomics (OTCMKTS:EPGNY) and Ortho Clinical Diagnostics (NASDAQ:OCDX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Profitability

This table compares Epigenomics and Ortho Clinical Diagnostics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and target prices for Epigenomics and Ortho Clinical Diagnostics, as provided by MarketBeat.com.

Ortho Clinical Diagnostics has a consensus price target of $24.2727, suggesting a potential upside of 30.99%. Given Ortho Clinical Diagnostics' higher possible upside, analysts clearly believe Ortho Clinical Diagnostics is more favorable than Epigenomics.

Earnings & Valuation

This table compares Epigenomics and Ortho Clinical Diagnostics' gross revenue, earnings per share and valuation.

Summary

Ortho Clinical Diagnostics beats Epigenomics on 2 of the 2 factors compared between the two stocks.

Epigenomics (OTCMKTS:EPGNY) and Biodesix (NASDAQ:BDSX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Valuation & Earnings

This table compares Epigenomics and Biodesix's top-line revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Epigenomics and Biodesix, as reported by MarketBeat.

Biodesix has a consensus price target of $26.00, suggesting a potential upside of 34.23%. Given Biodesix's higher possible upside, analysts clearly believe Biodesix is more favorable than Epigenomics.

Profitability

This table compares Epigenomics and Biodesix's net margins, return on equity and return on assets.

Summary

Biodesix beats Epigenomics on 2 of the 2 factors compared between the two stocks.

Epigenomics (OTCMKTS:EPGNY) and Lucira Health (NASDAQ:LHDX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Profitability

This table compares Epigenomics and Lucira Health's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Epigenomics and Lucira Health's top-line revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a breakdown of current ratings for Epigenomics and Lucira Health, as reported by MarketBeat.com.

Lucira Health has a consensus price target of $9.00, indicating a potential upside of 14.80%. Given Lucira Health's higher probable upside, analysts clearly believe Lucira Health is more favorable than Epigenomics.

Summary

Lucira Health beats Epigenomics on 2 of the 2 factors compared between the two stocks.

Inotiv (NASDAQ:NOTV) and Epigenomics (OTCMKTS:EPGNY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Valuation and Earnings

This table compares Inotiv and Epigenomics' gross revenue, earnings per share and valuation.

Profitability

This table compares Inotiv and Epigenomics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for Inotiv and Epigenomics, as reported by MarketBeat.com.

Epigenomics (OTCMKTS:EPGNY) and Akumin (NASDAQ:AKU) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Profitability

This table compares Epigenomics and Akumin's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Epigenomics and Akumin, as provided by MarketBeat.com.

Valuation & Earnings

This table compares Epigenomics and Akumin's gross revenue, earnings per share (EPS) and valuation.

Insider and Institutional Ownership

30.4% of Akumin shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Akumin beats Epigenomics on 2 of the 2 factors compared between the two stocks.